Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice

BMC Microbiology

Volumn 9, Issue , 2009, Pages

  Leszczyska, Katarzyna ^a   Namiot, Andrzej ^a   Fein, David E ^b   Wen, Qi ^c   Namiot, Zbigniew ^a   Savage, Paul B ^d   Diamond, Scott ^b   Janmey, Paul A ^c   Bucki, Robert ^c  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Brigham Young University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDE; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CSA 13; PEPSIN A; STOMACH MUCIN; UNCLASSIFIED DRUG; WLBU 2; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE BINDING PROTEIN; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; CERAGENIN CSA 13; CERAGENIN CSA-13; STEROID; WLBU2 PEPTIDE;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG DEGRADATION; DRUG INHIBITION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; PROTEIN EXPRESSION; STOMACH JUICE; STOMACH MUCOSA; STOMACH PH; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; TUMOR CELL LINE;

HELICOBACTER PYLORI;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL LINE, TUMOR; GASTRIC JUICE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIAL SENSITIVITY TESTS; STEROIDS;

EID: 70349630154     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-9-187     Document Type: Article

References (37)

1. Helicobacter pylori and gastrointestinal tract adenocarcinomas. RM Peek Jr MJ Blaser, Nat Rev Cancer 2002 2 1 28 37 10.1038/nrc703 11902583
2. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. BJ Marshall JR Warren, Lancet 1984 1 8390 1311 1315 10.1016/S0140-6736(84)91816-6 6145023
3. Application of Bead-ELISA method to detect Helicobacter pylori VacA. H Nagata A Wada H Kurazono K Yahiro D Shirasaka T Ikemura N Aoyama AP Wang K Makiyama S Kohno, et al. Microb Pathog 1999 26 2 103 110 10.1006/mpat.1998.0256 10090857
4. New aspects of Helicobacter pylori infection involvement in gastric oncogenesis. J Kountouras C Zavos D Chatzopoulos P Katsinelos, J Surg Res 2008 146 1 149 158 10.1016/j.jss.2007.06.011 17720195
5. Helicobacter pylori evolution during progression from chronic atrophic gastritis to gastric cancer and its impact on gastric stem cells. M Giannakis SL Chen SM Karam L Engstrand JI Gordon, Proc Natl Acad Sci USA 2008 105 11 4358 4363 10.1073/pnas.0800668105 18332421
6. Helicobacter pylori and gastric malignancies. G Nardone A Morgner, Helicobacter 2003 8 Suppl 1 44 52 10.1046/j.1523-5378.2003.00160.x 14617217
7. Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. L Fuccio RM Zagari ME Minardi F Bazzoli, Aliment Pharmacol Ther 2007 25 2 133 141 17229238
8. Helicobacter pylori infection and gastric carcinogenesis in animal models. M Tatematsu K Nozaki T Tsukamoto, Gastric Cancer 2003 6 1 1 7 10.1007/s101200300000 12673420
9. Effect of Helicobacter pylori eradication on gastric carcinogenesis. J Romero-Gallo EJ Harris U Krishna MK Washington GI Perez-Perez RM Peek, Lab Invest 2008 88 3 328 336 10.1038/labinvest.3700719 18180700
10. Expression of human beta-defensin 2 (hBD-2) in Helicobacter pylori induced gastritis: antibacterial effect of hBD-2 against Helicobacter pylori. Y Hamanaka M Nakashima A Wada M Ito H Kurazono H Hojo Y Nakahara S Kohno T Hirayama I Sekine, Gut 2001 49 4 481 487 10.1136/gut.49.4.481 11559643
11. Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against Helicobacter pylori. K Hase M Murakami M Iimura SP Cole Y Horibe T Ohtake M Obonyo RL Gallo L Eckmann MF Kagnoff, Gastroenterology 2003 125 6 1613 1625 10.1053/j.gastro.2003.08.028 14724813
12. Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. M Kawakubo Y Ito Y Okimura M Kobayashi K Sakura S Kasama MN Fukuda M Fukuda T Katsuyama J Nakayama, Science 2004 305 5686 1003 1006 10.1126/science.1099250 15310903
13. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. OE Sorensen P Follin AH Johnsen J Calafat GS Tjabringa PS Hiemstra N Borregaard, Blood 2001 97 12 3951 3959 10.1182/blood.V97.12.3951 11389039
14. Antimicrobial peptides in defence of the oral and respiratory tracts. DA Devine, Mol Immunol 2003 40 7 431 443 10.1016/S0161-5890(03)00162-7 14568389
15. Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. MJ Nell GS Tjabringa AR Wafelman R Verrijk PS Hiemstra JW Drijfhout JJ Grote, Peptides 2006 27 4 649 660 10.1016/j.peptides.2005.09.016 16274847
16. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. A Elssner M Duncan M Gavrilin MD Wewers, J Immunol 2004 172 8 4987 4994 15067080
17. Peptide antimicrobial agents. H Jenssen P Hamill RE Hancock, Clin Microbiol Rev 2006 19 3 491 511 10.1128/CMR.00056-05 16847082
18. Antibacterial peptides-a bright future or a false hope. R Bucki I Levental PA Janmey, Anti-Infective Agents in Medicinal Chemistry 2007 6 175 184 10.2174/187152107781023665
19. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. B Deslouches K Islam JK Craigo SM Paranjape RC Montelaro TA Mietzner, Antimicrob Agents Chemother 2005 49 8 3208 3216 10.1128/AAC.49.8.3208- 3216.2005 16048927
20. Ceragenins: Cholic Acid-Based Mimics of Antimicrobial Peptides. XZ Lai Y Feng J Pollard JN Chin MJ Rybak R Bucki RF Epand RM Epand PB Savage, Acc Chem Res 2008 41 10 4936 4951 10.1021/ar700270t
21. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. JN Chin RN Jones HS Sader PB Savage MJ Rybak, J Antimicrob Chemother 2008 61 2 365 370 10.1093/jac/dkm457 18079128
22. Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. JN Chin MJ Rybak CM Cheung PB Savage, Antimicrob Agents Chemother 2007 51 4 1268 1273 10.1128/AAC.01325-06 17210765
23. The antimicrobial peptide cathelicidin interacts with airway mucus. K Felgentreff C Beisswenger M Griese T Gulder G Bringmann R Bals, Peptides 2006 27 12 3100 3106 10.1016/j.peptides.2006.07.018 16963160
24. Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13. R Bucki DB Namiot Z Namiot PB Savage PA Janmey, J Antimicrob Chemother 2008 62 2 329 335 10.1093/jac/dkn176 18456648
25. Lysozyme localization in normal and diseased human gastric and colonic mucosa. A correlative histochemical, immunohistochemical and immunoelectron microscopic investigation. D Santini G Pasquinelli G Mazzoleni MC Gelli P Preda M Taffurelli D Marrano G Martinelli, Apmis 1992 100 7 575 585 10.1111/j.1699-0463.1992.tb03969.x 1642844
26. Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. K Hase L Eckmann JD Leopard N Varki MF Kagnoff, Infect Immun 2002 70 2 953 963 10.1128/IAI.70.2.953-963.2002 11796631
27. What is new in the management of Helicobacter pylori? BJ Egan HJ O'Connor CA O'Morain, Ir J Med Sci 2008 177 3 185 188 10.1007/s11845-008-0173-8 18636309
28. New strategies for Helicobacter pylori eradication. M Selgrad P Malfertheiner, Curr Opin Pharmacol 2008 8 5 593 597 10.1016/j.coph.2008.04.010 18555746
29. Helicobacter pylori treatment: is sequential or quadruple therapy the answer? N Vakil, Rev Gastroenterol Disord 2008 8 2 77 82 18641590
30. Helicobacter pylori amoxicillin heteroresistance due to point mutations in PBP-1A in isogenic isolates. MJ Matteo G Granados M Olmos A Wonaga M Catalano, J Antimicrob Chemother 2008 61 3 474 477 10.1093/jac/dkm504 18192681
31. New concepts of resistance in the treatment of Helicobacter pylori infections. DY Graham A Shiotani, Nat Clin Pract Gastroenterol Hepatol 2008 5 6 321 331 10.1038/ncpgasthep1138 18446147
32. The cationic host defense peptide rCRAMP promotes gastric ulcer healing in rats. YH Yang WK Wu EK Tai HP Wong EK Lam WH So VY Shin CH Cho, J Pharmacol Exp Ther 2006 318 2 547 554 10.1124/jpet.106.102467 16670350
33. Cure of duodenal ulcer after eradication of Helicobacter pylori. LL George TJ Borody P Andrews M Devine D Moore-Jones M Walton S Brandl, Med J Aust 1990 153 3 145 149 1974027
34. Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics. B Ding Q Guan JP Walsh JS Boswell TW Winter ES Winter SS Boyd C Li PB Savage, J Med Chem 2002 45 3 663 669 10.1021/jm0105070 11806717
35. Antibacterial activities of rhodamine B-conjugated gelsolin-derived peptides compared to those of the antimicrobial peptides cathelicidin LL37, magainin II, and melittin. R Bucki JJ Pastore P Randhawa R Vegners DJ Weiner PA Janmey, Antimicrob Agents Chemother 2004 48 5 1526 1533 10.1128/AAC.48.5.1526- 1533.2004 15105101
36. Improving gastric transit, gastrointestinal persistence and therapeutic efficacy of the probiotic strain Bifidobacterium breve UCC2003. VM Sheehan RD Sleator C Hill GF Fitzgerald, Microbiology 2007 153 Pt 10 3563 3571 10.1099/mic.0.2007/006510-0 17906153
37. An investigation of the chemical stability of arsenosugars in basic environments using IC-ICP-MS and IC-ESI-MS/MS. BM Gamble PA Gallagher JA Shoemaker AN Parks DM Freeman CA Schwegel JT Creed, Analyst 2003 128 12 1458 1461 10.1039/b306931a 14737232